ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT06495125

Public ClinicalTrials.gov record NCT06495125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Defactinib and Avutometinib, in Combination With Nivolumab for Patients With Anti-PD1 Refractory LKB1-Mutant Advanced Lung Adenocarcinoma

Study identification

NCT ID
NCT06495125
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Emory University
Other
Enrollment
50 participants

Conditions and interventions

Interventions

  • Avutometinib Drug
  • Biopsy Procedure
  • Biospecimen Collection Procedure
  • Computed Tomography Procedure
  • Defactinib Drug
  • Nivolumab Biological
  • Positron Emission Tomography Procedure

Drug · Procedure · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2024
Primary completion
Mar 16, 2029
Completion
Sep 16, 2029
Last update posted
Apr 5, 2026

2024 – 2029

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Emory University Hospital Midtown Atlanta Georgia 30308 Not yet recruiting
Emory University Hospital/Winship Cancer Institute Atlanta Georgia 30322 Recruiting
Emory Saint Joseph's Hospital Atlanta Georgia 30342 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06495125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 5, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06495125 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →